Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia | Nature Communications
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments - ScienceDirect
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma | NEJM
Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram
Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer | NEJM
Event-free survival curves. The Kaplan-Meier curves demonstrate no... | Download Scientific Diagram
Are there differences between progression-free survival, relapse-free survival, and recurrence-free survival? | ResearchGate
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments - ScienceDirect
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments - ScienceDirect
PPT - Overall Survival and Progression-Free Survival PowerPoint Presentation - ID:4064400
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Event-free survival > Overall survival? - data analysis - Datamethods Discussion Forum
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
Overall survival (a) and disease-free survival (b) among the entire... | Download Scientific Diagram
Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia | Annals of Hematology
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology
